How do immunomodulators affect host defense in the burn patient?
D000276:Adjuvants, Immunologic / Q000627:therapeutic use*; D000818:Animals; D000911:Antibodies, Monoclonal / Q000276:immunology; D000917:Antibody Formation; D001407:Bacillus / Q000276:immunology; D002056:Burns / Q000276:immunology* / Q000628:therapy; D006801:Humans; D007111:Immunity, Cellular; D007113:Immunity, Innate; D007375:Interleukin-1 / Q000276:immunology; D007376:Interleukin-2 / Q000276:immunology; D009343:Neisseria / Q000276:immunology; D010446:Peptide Fragments / Q000627:therapeutic use; D010880:Piperidines / Q000627:therapeutic use; D011725:Pyridines; D013210:Staphylococcus / Q000276:immunology; D013291:Streptococcus / Q000276:immunology; D013438:Sulfhydryl Compounds; D013844:Thiazoles / Q000627:therapeutic use; D016305:Thymopentin; D013946:Thymopoietins / Q000627:therapeutic use; D014780:Viruses / Q000276:immunology; D014946:Wound Infection / Q000276:immunology* / Q000628:therapy
D000276:Adjuvants, Immunologic; D000911:Antibodies, Monoclonal; D007375:Interleukin-1; D007376:Interleukin-2; D010446:Peptide Fragments; D010880:Piperidines; D011725:Pyridines; D013438:Sulfhydryl Compounds; D013844:Thiazoles; D013946:Thymopoietins; C038408:CP 46665; C042683:pirtianol; C041551:fanetizole; D016305:Thymopentin